Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, China.
Department of Operational Medicinal Research, Tianjin Institute of Environmental and Operational Medicine, Tianjin 300050, China.
Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20204216.
Gualou Xiebai Banxia (GLXBBX) decoction is a well-known traditional Chinese herbal formula that was first discussed in the Synopsis of the Golden Chamber by Zhang Zhongjing in the Eastern Han Dynasty. In traditional Chinese medicine, GLXBBX is commonly prescribed to treat cardiovascular diseases, such as coronary heart disease and atherosclerosis.
The present study aimed to examine GLXBBX's preventative capacity and elucidate the potential molecular mechanism of Poloxamer 407 (P407)-induced hyperlipidemia in rats.
Both the control and model groups received pure water, and the test group also received a GLXBBX decoction. For each administration, 3 ml of the solution was administered orally. To establish hyperlipidemia, a solution mixed with 0.25 g/kg P407 dissolved in 0.9% normal saline was injected slowly into the abdominal cavity. At the end of the study, the rats' plasma lipid levels were calculated using an automatic biochemical analyzer to evaluate the preventative capability of the GLXBBX decoction, and the serum and liver of the rats were collected.
The GLXBBX decoction significantly improved P407-induced hyperlipidemia, including increased plasma triglycerides (TGs), aspartate aminotransferase (AST) elevation, and lipid accumulation. Moreover, GLXBBX decoction treatment increased lipoprotein lipase (LPL) activity and mRNA expression of LPL. Furthermore, GLXBBX significantly suppressed the mRNA expression of stearoyl-CoA desaturase (SCD1).
GLXBBX significantly improved P407-induced hyperlipidemia, which may have been related to enhanced LPL activity, increased LPL mRNA expression, and decreased mRNA expression of SCD1.
瓜蒌薤白半夏汤(GLXBBX)是一种著名的中药方剂,最早由东汉张仲景在《金匮要略》中讨论。在中医中,GLXBB 常用于治疗心血管疾病,如冠心病和动脉粥样硬化。
本研究旨在探讨 GLXBBX 的预防能力,并阐明泊洛沙姆 407(P407)诱导大鼠高血脂的潜在分子机制。
对照组和模型组给予纯净水,实验组同时给予 GLXBBX 汤。每次给药 3ml,口服。为建立高血脂症,将 0.25g/kg P407 溶于 0.9%生理盐水的溶液缓慢注入腹腔。研究结束时,用自动生化分析仪计算大鼠血浆脂质水平,评价 GLXBBX 汤的预防能力,并收集大鼠血清和肝脏。
GLXBBX 汤显著改善了 P407 诱导的高血脂症,包括血浆甘油三酯(TGs)升高、天冬氨酸转氨酶(AST)升高和脂质堆积。此外,GLXBBX 汤治疗可提高脂蛋白脂肪酶(LPL)活性和 LPL mRNA 表达。此外,GLXBBX 显著抑制硬脂酰辅酶 A 去饱和酶(SCD1)的 mRNA 表达。
GLXBBX 显著改善了 P407 诱导的高血脂症,这可能与增强 LPL 活性、增加 LPL mRNA 表达和降低 SCD1 mRNA 表达有关。